

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Fusen Pharmaceutical Company Limited**

**福森藥業有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1652)**

### **VOLUNTARY ANNOUNCEMENT APPLICATION FOR LAUNCHING**

#### **“COMPOUND POTASSIUM PHOSPHATE INJECTION” BEING ACCEPTED**

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) is pleased to announce that the application for launching “Compound Potassium Phosphate Injection” developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited\* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has been submitted to and accepted by the National Medical Products Administration of the People’s Republic of China. The product is used for the treatment of the following diseases: as a phosphorus supplement in total gastrointestinal nutrition therapy; It is also for the treatment of hypophosphatemia caused by certain diseases.

Phosphorus is involved in sugar phosphorylation in glucose metabolism, which constitutes a phospholipid in membrane composition and is one of the important components of intracellular RNA, DNA and many coenzymes. Phosphorus is also involved in the energy storage conversion, transmission and regulation of body fluid buffering function. “Compound Potassium Phosphate Injection” is a phosphorus supplement, which is for the treatment of hypophosphatemia in adult and pediatric patients by intravenous infusion when oral or enteral supplementation is impossible, insufficient, or contraindicated, and for parenteral nutrition in adult and pediatric patients when oral or enteral nutrition is impossible, insufficient, or contraindicated.

Hypophosphatemia is usually asymptomatic and present in up to 5% of patients. It is more prevalent in alcoholism, diabetic ketoacidosis or sepsis, with a frequency of up to 80%. Hypophosphatemia can occur in people of all ages and genders, and can be asymptomatic in mild cases or lead to serious clinical consequences in severe cases.

\* For identification purposes only

This product is a Class B drug in medical insurance and a national-based drug. It has the characteristics of high safety, rapid absorption and onset of effect, dual supplementation of phosphorus and potassium, and multi-guideline consensus. The “Compound Potassium Phosphate Injection” developed by the Company is declared as a class 3 chemical drugs, and its prescription is basically the same as the original reference preparations, and the quality of the products is strictly controlled to ensure that its quality is better than or consistent with the original preparation products, so as to ensure the medication safety of patients. In addition, a non-clinical safety study was conducted in accordance with regulatory requirements, and the results showed that the special safety of the product was consistent with the reference preparations. “Compound Potassium Phosphate Injection” provides a very favourable risk-benefit ratio in the treatment of hypophosphatemia and parenteral nutrition requiring phosphorus supplementation, and in the improvement of laboratory findings and clinical symptoms in adult and pediatric patients.

“Compound Potassium Phosphate Injection” is another important product of the Group, which further enriches the Group’s product pipeline in the therapeutic area of nutritional supplements. The launch of this product will provide more therapeutic options for adult and pediatric patients with hypophosphatemia and parenteral nutrition.

By order of the Board  
**Fusen Pharmaceutical Company Limited**  
**Mr. Cao Changcheng**  
*Chairman and Executive Director*

Hong Kong, 23 April 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfeng and Mr. Cao Zhiming as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.*